Lucira Health, Inc.
LHDX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 31.5% | -71.1% | 48% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | -289.5% | 30.6% | 44.1% | 20.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -367.2% | -81.8% | 15.3% | -12.8% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -368.9% | -82.9% | 14.5% | -12.3% |
| EPS | -3.15 | -0.54 | 0.31 | -0.19 |
| % Growth | -483.3% | -274.2% | 263.2% | – |
| EPS Diluted | -3.15 | -0.54 | 0.31 | -0.19 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -361% | -74.3% | 15.4% | -10.7% |